By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Panelists agree that Lilly's growth is driven by Mounjaro and Zepbound, but they differ on the sustainability of this growth due to pricing pressure, competition, and concentration risk. The potential inclusion of obesity drugs in Medicare Part D coverage is a debated opportunity.
Risk: Cannibalization of high-margin injectables by Foundayo and continued price erosion.
Opportunity: Potential inclusion of obesity drugs in Medicare Part D coverage.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Eli Lilly (NYSE: LLY) commands a market capitalization of about $1.06 trillion, and that valuation was built largely on two drugs: Mounjaro and Zepbound. Investors talk about the drugmaker's weight-loss and diabetes franchise constantly. But it's worth pinning down what these medicines actually contribute, and the company's most recent quarterly report gives a concrete answer.
In the first quarter of 2026, Mounjaro and Zepbound generated a combined $12.8 billion in revenue. That was almost two-thirds of Lilly's $19.8 billion in total revenue for the period -- a bigger share than I suspect many investors realize.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
A franchise still accelerating
Mounjaro, Lilly's tirzepatide-based treatment for type 2 diabetes, saw worldwide first-quarter revenue jump 125% year over year to $8.7 billion. Zepbound, the same molecule marketed for weight loss, grew revenue 80% to $4.2 billion.
And the pair's momentum isn't new. The two drugs combined for $6.2 billion of revenue in the first quarter of 2025, $11.7 billion in the fourth quarter, and $12.8 billion in the most recent period, meaning the franchise has more than doubled in a year and is still climbing quarter by quarter. For full-year 2025, the pair brought in $36.5 billion, more than half of Lilly's $65.2 billion in revenue.
Even more impressive, Mounjaro's growth rate is accelerating. It rose 99% for full-year 2025, 110% in the fourth quarter, and 125% in the most recent quarter. That is extraordinary acceleration for a product already generating billions of dollars every quarter.
Lilly's total first-quarter revenue rose 56% year over year, driven by a 65% increase in volume, partially offset by a 13% decline in realized prices. Growth was global, too, with U.S. revenue up 43% and revenue outside the U.S. up 81%.
And the surging franchise is showing up on the bottom line. Lilly's first-quarter earnings per share soared 170% year over year to $8.26, and non-GAAP (adjusted) earnings per share rose 156% to $8.55.
On the strength of the quarter, management raised its full-year revenue outlook to a range of $82 billion to $85 billion, a $2 billion increase from its prior forecast, and lifted its adjusted earnings-per-share guidance by $2 as well. The new revenue range implies growth of about 28% at the midpoint compared with 2025.
The pill, the pricing, and the price tag
In April, the franchise gained a third member. The FDA approved Foundayo, Lilly's once-daily orforglipron pill, for adults with obesity or overweight adults with weight-related medical problems. Lilly says it is the only GLP-1 (glucagon-like peptide-1) pill for weight loss that can be taken any time of day without food or water restrictions. And the company moved fast, opening prescriptions immediately and beginning shipments within a week of approval.
With self-pay pricing that starts at $149 per month for the lowest dose, the pill may open the market well beyond the population willing and able to take weekly injections.
Of course, the same concentration that makes the franchise valuable also makes it a risk. Nearly two-thirds of Lilly's revenue now rides on one molecule in one therapeutic area. And realized prices are falling, down 13% in the first quarter, including reductions in cash-pay prices for Zepbound.
Volume growth has overwhelmed the pricing pressure so far. If that ever flips, the market's enthusiasm could flip with it.
This brings us to the valuation. At about $1,184 per share as of this writing, Lilly trades at about 33 the midpoint of management's adjusted guidance range of $35.50 to $37.00 per share. That is a premium multiple, but it's attached to a company guiding for about 28% revenue growth -- and one that just raised that guidance by $2 billion.
So, how much are the weight-loss drugs worth to investors? They aren't a piece of the story -- they're most of it, accounting for nearly two-thirds of revenue and most of the company's growth. I think that premium is arguably earned at today's growth rates, and the new pill gives the franchise more runway.
Investors just need to know exactly what they own here. This is a trillion-dollar company whose results ride largely on one extraordinary family of medicines. That's a big opportunity, but also a big risk.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $395,679!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,294,805!*
Now, it's worth noting Stock Advisor's total average return is 929% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Daniel Sparks and his clients do not have positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy.
Four leading AI models discuss this article
"LLY's premium 33x valuation is earned only if tirzepatide volume acceleration continues to overwhelm intensifying pricing and competition risks that the article understates."
The article correctly highlights that Mounjaro and Zepbound drove ~65% of LLY's Q1 2026 revenue ($12.8B of $19.8B) with 125% and 80% Y/Y growth, respectively, fueling a 170% EPS surge and upward guidance revision to $82-85B revenue (~28% growth). The new oral orforglipron (Foundayo) at $149/month self-pay expands TAM. However, the piece downplays accelerating pricing pressure (-13% realized prices) and extreme concentration risk: one molecule (tirzepatide) in one therapeutic area now dominates a $1.06T market cap trading at 33x forward EPS.
GLP-1 competition is intensifying from Novo Nordisk, Amgen, and emerging oral/weekly alternatives; supply constraints are easing while payer pushback on high list prices grows. If volume growth decelerates below 40-50% while pricing erodes another 10-15%, the 33x multiple could compress sharply toward 20-22x, erasing hundreds of billions in market value.
"The 13% decline in realized pricing is a critical warning sign that volume-driven growth is masking accelerating margin pressure in the GLP-1 franchise."
Eli Lilly's 33x forward P/E is historically rich for a pharma company, but the 28% revenue growth trajectory justifies the premium IF they maintain current supply chain velocity. The 13% decline in realized pricing is the 'canary in the coal mine'—it signals that payor pressure and competitive biosimilar/generic threats are already eroding margins despite volume growth. While Foundayo’s $149 price point expands the TAM (Total Addressable Market) significantly, it also invites margin compression. Investors are currently pricing in perfection; any supply chain hiccup or further price erosion will result in a violent multiple contraction as the market re-evaluates LLY as a commodity-sensitive utility rather than a high-growth tech-like biotech.
If Lilly’s oral Foundayo successfully captures the mass-market, non-injectable segment, the volume expansion could more than offset price per unit, potentially leading to a massive earnings surprise that makes a 33x multiple look cheap in hindsight.
"LLY's 33x forward multiple is defensible only if tirzepatide pricing stabilizes and volume growth doesn't decelerate — neither is guaranteed as the obesity market commoditizes."
LLY's valuation hinges on a 33x forward P/E multiple justified by 28% revenue guidance — but that math only works if tirzepatide maintains pricing power and market share against incoming competition. The article celebrates Mounjaro's 125% YoY growth while burying a critical detail: realized prices fell 13% in Q1. Volume is masking erosion. Foundayo's $149/month entry price signals Lilly is racing downmarket before competitors (Novo Nordisk, Viking, Structure) fragment the obesity market. Two-thirds of revenue from one molecule in one indication is not a feature — it's a concentration bet. The article treats this as 'earned premium,' but premium multiples evaporate when growth decelerates or pricing inflects negative.
If Foundayo captures price-sensitive patients Lilly couldn't reach before, and if tirzepatide's clinical superiority holds against generics for 5+ years, the franchise could sustain 20%+ growth through 2030, justifying current multiples and making today's 'concentration risk' look like a non-issue in hindsight.
"The stock’s upside hinges on sustained 28% revenue growth and price resilience from Lilly’s weight-loss franchise, plus Foundayo expansion, but faces meaningful risks if demand slows or competition intensifies."
Here's my take: Lilly's story hinges on Mounjaro and Zepbound, with Q1 2026 revenue of $12.8B and two-thirds of total sales, plus the Foundayo pill expanding the addressable market. The momentum is impressive—growth in both units and margins—yet the thesis hides important headwinds: (1) price erosion is already running (~13% realized price decline in Q1), (2) the market's long-term demand is contingent on payer coverage and patient access, not just prescriptions, (3) the franchise is highly concentrated in a single molecule/therapy area, creating big single-point risk, and (4) potential competition from Novo Nordisk and other GLP-1s could compress growth. The valuation looks rich but defensible if growth proves durable.
The bear case is simple: the growth engine rests on tirzepatide in one therapy area, and sustained demand, payer support, and relative price resilience are not guaranteed—any hiccup could trigger outsized multiple compression.
"Foundayo's low price point risks faster cannibalization of tirzepatide's high-margin injectable sales, amplifying realized price erosion beyond current 13%."
Nobody has flagged that easing supply + oral entry at $149 accelerates cannibalization of high-margin injectables. As Foundayo scales, realized pricing could fall another 8-12% across the franchise, not just 13% in Q1. This turns the 28% revenue guide into mostly volume-dependent math at declining ASPs, making 33x forward EPS look even more vulnerable if volume growth slips below 45%.
"CMS coverage expansion will likely offset margin compression by driving massive volume growth that renders current pricing concerns secondary."
Grok and Claude are missing the regulatory tailwind: the CMS's potential inclusion of obesity drugs in Part D coverage. If Medicare subsidizes these, the 'pricing pressure' narrative flips. The 13% realized price decline isn't just competitive erosion; it's a strategic trade-off for formulary access. If Lilly secures broad coverage, the volume surge will dwarf the margin compression. The real risk isn't cannibalization—it's the political ceiling on drug pricing if these costs bankrupt public health budgets.
"Medicare coverage expands volume but locks in lower realized prices—a revenue growth story masking per-unit margin decay."
Gemini's Medicare coverage thesis is plausible but sidesteps the math: CMS Part D inclusion doesn't reverse cannibalization—it accelerates it. Broader coverage + lower copays = higher volume at *lower* net prices. The 13% Q1 erosion predates major Medicare action, suggesting competitive/payer pressure is already structural. Political pricing ceilings are real, but they're a *downside* tail risk, not a tailwind that justifies 33x forward multiples. Volume surge doesn't 'dwarf' margin compression if ASPs keep falling.
"Medicare coverage alone won't guarantee margin expansion; Part D pricing dynamics keep net prices under pressure, so the high multiple remains vulnerable unless volume growth and ASP mix outperform assumptions."
Gemini's Medicare tailwind claim overestimates how coverage translates into durable EBITDA: Part D would bring rebates and strict formulary positioning that often narrows net prices, and ramp time could mute near-term volume gains. Even if Foundayo expands TAM, the combination of continued ASP erosion, competition, and political price-controls keeps the risk to margin and the 33x multiple skewed toward a bigger downside surprise if volume stalls.
Panelists agree that Lilly's growth is driven by Mounjaro and Zepbound, but they differ on the sustainability of this growth due to pricing pressure, competition, and concentration risk. The potential inclusion of obesity drugs in Medicare Part D coverage is a debated opportunity.
Potential inclusion of obesity drugs in Medicare Part D coverage.
Cannibalization of high-margin injectables by Foundayo and continued price erosion.